GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ocugen Inc (FRA:2H51) » Definitions » PS Ratio

Ocugen (FRA:2H51) PS Ratio : 51.73 (As of Apr. 25, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Ocugen PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Ocugen's share price is €1.138. Ocugen's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was €0.02. Hence, Ocugen's PS Ratio for today is 51.73.

The historical rank and industry rank for Ocugen's PS Ratio or its related term are showing as below:

FRA:2H51' s PS Ratio Range Over the Past 10 Years
Min: 16.39   Med: 4060   Max: 48085
Current: 52.08

During the past 12 years, Ocugen's highest PS Ratio was 48085.00. The lowest was 16.39. And the median was 4060.00.

FRA:2H51's PS Ratio is ranked worse than
79.41% of 991 companies
in the Biotechnology industry
Industry Median: 8.98 vs FRA:2H51: 52.08

Ocugen's Revenue per Sharefor the three months ended in Dec. 2023 was €0.02. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was €0.02.

During the past 12 months, the average Revenue per Share Growth Rate of Ocugen was 108.30% per year.

Back to Basics: PS Ratio


Ocugen PS Ratio Historical Data

The historical data trend for Ocugen's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ocugen PS Ratio Chart

Ocugen Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 108.33 23.00

Ocugen Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 108.33 77.55 49.37 36.36 23.00

Competitive Comparison of Ocugen's PS Ratio

For the Biotechnology subindustry, Ocugen's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ocugen's PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ocugen's PS Ratio distribution charts can be found below:

* The bar in red indicates where Ocugen's PS Ratio falls into.



Ocugen PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Ocugen's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=1.138/0.022
=51.73

Ocugen's Share Price of today is €1.138.
Ocugen's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.02.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


Ocugen  (FRA:2H51) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Ocugen PS Ratio Related Terms

Thank you for viewing the detailed overview of Ocugen's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Ocugen (FRA:2H51) Business Description

Traded in Other Exchanges
Address
11 Great Valley Parkway, Malvern, PA, USA, 19355
Ocugen Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19. The breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug one to many and novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema and diabetic retinopathy. The company is co-developing Bharat Biotech's COVAXIN vaccine candidate for COVID-19 in the U.S. and Canadian markets.

Ocugen (FRA:2H51) Headlines

No Headlines